Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
METROCREAM vs ABSTRAL
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Metrocream contains metronidazole, a nitroimidazole antibiotic. Its mechanism involves reduction of the nitro group by bacterial nitroreductases, forming toxic intermediates that damage DNA and inhibit nucleic acid synthesis. It also exhibits anti-inflammatory effects by reducing reactive oxygen species and modulating neutrophil chemotaxis.
Fentanyl is a potent mu-opioid receptor agonist, producing analgesia and sedation by activating G-protein coupled opioid receptors in the central nervous system.
Rosacea (inflammatory papules and pustules),Topical treatment of bacterial vaginosis (off-label)
Management of breakthrough pain in cancer patients aged 18 and older who are already receiving and tolerant to around-the-clock opioid therapy for their underlying persistent cancer pain.
Topical, apply a thin film to affected area once or twice daily.
For breakthrough pain in opioid-tolerant patients: initial dose 100 mcg sublingual tablet, titrate across strengths (100, 200, 300, 400, 600, 800 mcg) as needed; maximum 2 doses per episode, minimum 2 hours between episodes.
Terminal elimination half-life: 6-8 hours. Not extended in renal impairment.
Terminal elimination half-life: 6-10 hours (mean 8 hours); prolonged in elderly and hepatic impairment
Hepatic metabolism via oxidation and glucuronidation. Metronidazole is metabolized by CYP450 enzymes, primarily CYP2A6 and CYP3A4, forming metabolites such as hydroxy metronidazole and acetic acid metabolite.
Hepatic metabolism primarily via CYP3A4; major metabolites include norfentanyl (inactive) and other minor metabolites.
Renal: 70-80% as unchanged drug and metabolites. Fecal/biliary: ~20%.
Renal: ~70% as metabolites (primarily fentanyl conjugates and norfentanyl), ~10% unchanged; Fecal: ~9%; Biliary: minimal
Metronidazole: <20% bound to plasma proteins.
80-85% bound primarily to albumin and alpha-1-acid glycoprotein
Vd: ~0.6-0.7 L/kg, indicating distribution into total body water.
4-6 L/kg; large Vd indicates extensive tissue distribution
Topical: Systemic bioavailability approximately 0.1-1% of applied dose for metronidazole 1% cream.
Sublingual: 70-90% (mean 80%); buccal: 50-65%; oral: ~30% due to first-pass metabolism
No adjustment required for topical application.
No specific GFR-based dose adjustment recommended; use caution in severe renal impairment (Cr Cl <30 m L/min) due to potential accumulation of fentanyl.
No adjustment required for topical application.
For Child-Pugh Class A or B: no adjustment required; for Child-Pugh Class C: reduce dose and monitor closely for toxicity due to reduced clearance.
Safety and efficacy not established in pediatric patients under 18 years.
Not approved for pediatric patients <18 years; safety and efficacy not established.
No specific dose adjustment recommended; use caution due to potential skin atrophy.
Initiate at the lowest available dose (100 mcg) and titrate cautiously; elderly patients may have altered pharmacokinetics and increased sensitivity to fentanyl.
None
Risk of respiratory depression, addiction, abuse, and misuse; risk of accidental ingestion; risk of medication errors resulting in fatal overdose; life-threatening respiratory depression in opioid-non-tolerant patients; risk of opioid analgesic drug interactions with CNS depressants; risk of neonatal opioid withdrawal syndrome with prolonged use during pregnancy.
Avoid contact with eyes. Use with caution in patients with blood dyscrasias or history of hypersensitivity to metronidazole. Prolonged use may result in overgrowth of non-susceptible organisms. Discontinue if irritation occurs.
Respiratory depression, QT prolongation, serotonin syndrome, adrenal insufficiency, severe hypotension, seizures, biliary tract disease, gastrointestinal obstruction, withdrawal syndrome, and risk of overdose with alcohol or other CNS depressants.
Hypersensitivity to metronidazole or any component of the formulation.
Hypersensitivity to fentanyl or any components; opioid-non-tolerant patients; acute or severe bronchial asthma; known or suspected gastrointestinal obstruction; concurrent use of MAOIs or within 14 days of discontinuation.
No significant food interactions due to negligible systemic absorption. However, alcohol consumption should be avoided during treatment and for at least 48 hours after discontinuing metronidazole, as trace systemic absorption may cause disulfiram-like reactions (nausea, vomiting, flushing, headache).
Avoid grapefruit and grapefruit juice during treatment as they inhibit CYP3A4, increasing fentanyl exposure. No other significant food interactions; however, avoid alcohol due to additive CNS depressant effects. Maintain consistent meal timing relative to dosing to minimize variability.
Topical metronidazole (Metro Cream) is considered low risk for teratogenicity. In animal studies, no evidence of fetal harm was observed at topical doses. For oral metronidazole, data do not suggest an increased risk of major malformations; however, use in first trimester is generally avoided due to theoretical risk. For topical application, systemic absorption is minimal (approximately 2%), and the drug is considered safe throughout pregnancy, with no known fetal risks.
FDA Pregnancy Category C. First trimester: Inadequate human data; opioid analgesics are not associated with major malformations but may cause neural tube defects at high doses in animal studies. Second trimester: No specific malformation risk. Third trimester: Prolonged use can cause neonatal opioid withdrawal syndrome (NOWS) and respiratory depression at birth.
Minimal systemic absorption of metronidazole after topical application (approximately 2%) results in negligible transfer into breast milk. M/P ratio is not established for topical route. Use during breastfeeding is considered compatible; however, avoid application to breast area to prevent infant exposure.
Minimal excretion into breast milk; M/P ratio not reported. Fentanyl is poorly absorbed orally, making significant infant exposure unlikely. Monitor infant for sedation, respiratory depression, and poor feeding. Avoid use in breastfeeding mothers with opioid dependence or high doses.
No dosage adjustment is necessary during pregnancy. Systemic absorption from topical application is minimal and pharmacokinetic changes in pregnancy do not warrant dose modification.
Pregnancy increases clearance and volume of distribution, potentially reducing drug levels. Dose adjustments may be needed: initiate with lower doses and titrate to effect; consider increasing frequency or using breakthrough doses. Monitor for inadequate analgesia. Avoid abrupt discontinuation; taper if stopping.
Metronidazole topical cream is contraindicated in patients with a history of hypersensitivity to metronidazole or other nitroimidazole derivatives. Avoid contact with eyes, mucous membranes, or open wounds. Use during pregnancy only if clearly needed (FDA category B). Warn patients that topical metronidazole may cause transient skin irritation or dryness; if severe, discontinue use. Combine with sunscreen and photoprotective measures due to potential photosensitivity. For rosacea, clinical improvement may take 3–4 weeks; adherence is critical. Do not use with concomitant oral metronidazole or disulfiram-like reactions due to minimal systemic absorption.
ABSTRAL (fentanyl sublingual spray) is a transmucosal immediate-release fentanyl (TIRF) formulation indicated for breakthrough pain in opioid-tolerant patients. Due to high bioavailability (~70%) and rapid onset (peak plasma concentration at 15-30 minutes), initial titration must start with 100 mcg, with dose escalation based on efficacy and tolerability. Weight-based conversion from other fentanyl products is not valid; utilize the provided conversion table. Patients must have a rescue agent (e.g., naloxone) available. Concomitant use with CYP3A4 inhibitors (e.g., ketoconazole, ritonavir) or inducers (e.g., rifampin, carbamazepine) requires dose adjustment. Avoid use in opioid-naïve patients due to risk of respiratory depression.
Apply a thin layer to affected areas once or twice daily as directed.,Wash hands before and after application; avoid contact with eyes, mouth, and nostrils.,Do not use cosmetics or other skin products on treated areas unless approved by your doctor.,May cause mild stinging, burning, or dryness; if severe, stop use and inform your physician.,Minimize sun exposure and use sunscreen daily as metronidazole may increase sun sensitivity.,Notify your doctor if you develop signs of allergic reaction: rash, itching, swelling, or trouble breathing.,Do not use more than prescribed; extended use may lead to bacterial resistance.,If you are pregnant, planning to become pregnant, or breastfeeding, discuss with your doctor before using.,Inform your doctor if you are taking oral metronidazole or have a history of blood disorders or neuropathy.
Use only for breakthrough cancer pain while on around-the-clock opioid therapy.,Do not switch from other fentanyl products based on dose; follow specific conversion instructions.,Spray entire dose into mouth; do not swallow or rinse for at least 10 minutes.,Store at room temperature, away from children and pets.,Dispose of unused units via drug take-back program or by flushing down toilet per FDA guidelines.,Never share this medication with others; death may occur.,Seek emergency if severe drowsiness, confusion, or slow breathing occurs.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about METROCREAM vs ABSTRAL, answered by our medical review team.
METROCREAM is a Antibiotic (Nitroimidazole) that works by Metrocream contains metronidazole, a nitroimidazole antibiotic. Its mechanism involves reduction of the nitro group by bacterial nitroreductases, forming toxic intermediates that damage DNA and inhibit nucleic acid synthesis. It also exhibits anti-inflammatory effects by reducing reactive oxygen species and modulating neutrophil chemotaxis.. ABSTRAL is a Opioid Analgesic that works by Fentanyl is a potent mu-opioid receptor agonist, producing analgesia and sedation by activating G-protein coupled opioid receptors in the central nervous system.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between METROCREAM and ABSTRAL depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of METROCREAM is: Topical, apply a thin film to affected area once or twice daily.. The standard adult dose of ABSTRAL is: For breakthrough pain in opioid-tolerant patients: initial dose 100 mcg sublingual tablet, titrate across strengths (100, 200, 300, 400, 600, 800 mcg) as needed; maximum 2 doses per episode, minimum 2 hours between episodes.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between METROCREAM and ABSTRAL in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. METROCREAM is classified as Category C. Topical metronidazole (MetroCream) is considered low risk for teratogenicity. In animal studies, no evidence of fetal harm was observed at topical doses. For oral metronidazole, da. ABSTRAL is classified as Category C. FDA Pregnancy Category C. First trimester: Inadequate human data; opioid analgesics are not associated with major malformations but may cause neural tube defects at high doses in a. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.